INBSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends June 30
INTELLIGENT BIO SOLUTIONS INC.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K/A on Oct 21, 2026
$1.53+0.03 (+2.00%)
Close on Oct 19, 2026
- Market cap
- $3.83M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
6.0%
0M of 3M shares
Institutional holders
8
1 new, 2 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Anand Parekh | 944,310 | 9.99% | 13G (passive) amendment | Sep 30, 2025 |
| Steven Boyd | 141,397 | 5.91% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of INBS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 141,397 | 4.67% | $324.51K | +11,397 | 0.00% |
| Geode Capital Management, LLC | 20,840 | 0.69% | $47.83K | −7,769 | 0.00% |
| Vanguard Capital Management LLC | 5,810 | 0.19% | $13.33K | – | 0.00% |
| UBS Group AG | 5,735 | 0.19% | $13.16K | +5,363 | 0.00% |
| Vanguard Fiduciary Trust Co | 3,958 | 0.13% | $9.08K | – | 0.00% |
| Tower Research Capital LLC (TRC) | 3,280 | 0.11% | $7.53K | +2,030 | 0.00% |
| Osaic Holdings, Inc. | 200 | 0.01% | $460 | – | 0.00% |
| Barclays PLC | 142 | 0.00% | $326 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 8 | 0M | 6.0% | 1 / 3 | 1 / 2 | 0M | 0M |
| Q1 2026 | 9 | 0M | 6.9% | 6 / 0 | 2 / 4 | 0M | 0M |
| Q4 2025 | 7 | 0M | 0.2% | 7 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of INBS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 12,545 | 0.41% | $32.24K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 5,810 | 0.19% | $13.33K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 1,769 | 0.06% | $4.55K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 409 | 0.01% | $1.05K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -30 | -0.00% | -$69 | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Harry Simeonidis | Chief Executive Officer | 34,540 | 1.14% | Mar 20, 2026 |
| Spiro Kevin Sakiris | Chief Financial Officer | 35,892 | 1.19% | Mar 20, 2026 |
| Steven Constantine Boyages | Director | 5,031 | 0.17% | Mar 20, 2026 |
| Jonathan Scott Hurd | Director | 5,006 | 0.17% | Mar 20, 2026 |
| Jason Isenberg | Director | 5,000 | 0.17% | Mar 20, 2026 |
| Nicola Marion Fraser | Director | 5,000 | 0.17% | Mar 20, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Harry Simeonidis Chief Executive Officer | Mar 18, 2026 | Award | +21,350 | – | – | 34,540 |
| Harry Simeonidis Chief Executive Officer | Mar 18, 2026 | Award | +9,150 | – | – | 13,190 |
| Jason Isenberg Director | Mar 18, 2026 | Award | +5,000 | – | – | 5,000 |
| Steven Constantine Boyages Director | Mar 18, 2026 | Award | +5,000 | – | – | 5,031 |
| Jonathan Scott Hurd Director | Mar 18, 2026 | Award | +5,000 | – | – | 5,006 |
| Nicola Marion Fraser Director | Mar 18, 2026 | Award | +5,000 | – | – | 5,000 |
| Spiro Kevin Sakiris Chief Financial Officer | Mar 18, 2026 | Award | +21,350 | – | – | 33,981 |
| Spiro Kevin Sakiris Chief Financial Officer | Mar 18, 2026 | Award | +9,150 | – | – | 12,631 |
| Spiro Kevin Sakiris Chief Financial Officer | Sep 25, 2024 | Award | +34,500 | – | – | 34,815 |
| Spiro Kevin Sakiris Chief Financial Officer | Sep 25, 2024 | Award | +34,500 | – | – | 34,815 |
| Harry Simeonidis Chief Executive Officer | Sep 25, 2024 | Award | +40,000 | – | – | 40,408 |
| Spiro Kevin Sakiris Chief Financial Officer | Mar 20, 2024 | Option exercise | +9,394 | – | – | 19,180 |
| Spiro Kevin Sakiris Chief Financial Officer | Oct 4, 2023 | Buy | +112,727 | – | – | 117,427 |
| Christopher Towers Director | Oct 4, 2023 | Buy | +9,090 | – | – | 9,880 |
| Harry Simeonidis CEO | Sep 1, 2023 | Buy | +50 | $1.85 | $93 | 4,180 |
| Harry Simeonidis CEO | Aug 31, 2023 | Buy | +100 | $1.92 | $192 | 4,130 |
| Spiro Kevin Sakiris Chief Financial Officer | May 10, 2023 | Conversion | +2,399 | $5.80 | $13.91K | 4,745 |
| Spiro Kevin Sakiris Chief Financial Officer | Oct 10, 2022 | Award | +75,000 | – | – | 125,228 |
| George Margelis Director | Oct 10, 2022 | Award | +15,000 | – | – | 15,000 |
| Harry Simeonidis President | Oct 10, 2022 | Award | +80,000 | – | – | 80,600 |
| Jonathan Scott Hurd Director | Oct 10, 2022 | Award | +15,000 | – | – | 15,000 |
| Christopher Towers Director | Oct 10, 2022 | Award | +15,000 | – | – | 15,800 |
| Steven Constantine Boyages Interim CEO and Chairperson, Director | Oct 10, 2022 | Award | +75,000 | – | – | 75,000 |
| Lawrence B. Fisher Director | Oct 10, 2022 | Award | +15,000 | – | – | 15,000 |
| Spiro Kevin Sakiris Chief Financial Officer | Jun 22, 2022 | Buy | +5,000 | $0.65 | $3.25K | 50,228 |
| Spiro Kevin Sakiris ChiefFinancial Officer | Jun 17, 2022 | Buy | +15,970 | $0.61 | $9.74K | 45,228 |
| Science Biosensor Diagnostics Pty Ltd Life – | Feb 17, 2022 | Sale | −576,028 | $0.51 | $293.77K | 1,081,804 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Feb 16, 2022 | Sale | −100,000 | $0.63 | $63.00K | 1,657,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Feb 15, 2022 | Sale | −100,000 | $0.68 | $68.00K | 1,757,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Feb 14, 2022 | Sale | −100,000 | $0.70 | $70.00K | 1,857,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Feb 11, 2022 | Sale | −100,000 | $0.75 | $75.00K | 1,957,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Feb 10, 2022 | Sale | −100,000 | $0.84 | $84.00K | 2,057,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Feb 9, 2022 | Sale | −100,000 | $0.86 | $86.00K | 2,157,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Feb 8, 2022 | Sale | −100,000 | $0.89 | $89.00K | 2,257,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Feb 2, 2022 | Sale | −100,000 | $0.92 | $92.00K | 2,357,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Jan 31, 2022 | Sale | −100,000 | $0.90 | $90.00K | 2,457,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Jan 28, 2022 | Sale | −100,000 | $0.92 | $92.00K | 2,557,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Jan 27, 2022 | Sale | −100,000 | $1.00 | $100.00K | 2,657,832 |
| Tom Parmakellis Director | Dec 30, 2021 | Buy | +4,500 | $1.55 | $6.98K | 9,300 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Dec 17, 2021 | Sale | −200,000 | $1.49 | $298.00K | 2,757,832 |
| Tom Parmakellis Director | Dec 16, 2021 | Buy | +2,800 | $1.69 | $4.73K | 4,800 |
| Spiro Kevin Sakiris ChiefFinancial Officer | Dec 6, 2021 | Buy | +10,000 | $1.70 | $17.00K | 29,258 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Nov 30, 2021 | Sale | −250,000 | $1.87 | $467.50K | 2,957,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Nov 29, 2021 | Sale | −100,000 | $1.69 | $169.00K | 3,207,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Nov 24, 2021 | Sale | −100,000 | $1.64 | $164.00K | 3,307,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Nov 9, 2021 | Sale | −300,000 | $2.02 | $606.00K | 3,407,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Oct 21, 2021 | Sale | −248,416 | $2.26 | $561.42K | 3,707,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Oct 20, 2021 | Sale | −24,209 | $2.25 | $54.47K | 3,956,248 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Oct 19, 2021 | Sale | −16,326 | $2.25 | $36.73K | 3,980,457 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Oct 14, 2021 | Sale | −100,726 | $2.18 | $219.58K | 3,996,783 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Oct 13, 2021 | Sale | −58,739 | $2.25 | $132.16K | 4,097,509 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Oct 12, 2021 | Sale | −100,000 | $2.13 | $213.00K | 4,156,248 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Oct 8, 2021 | Sale | −200,000 | $2.30 | $460.00K | 4,256,248 |
| Tom Parmakellis Director | Sep 28, 2021 | Buy | +1,000 | $2.40 | $2.40K | 2,000 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Sep 28, 2021 | Sale | −200,000 | $2.48 | $496.00K | 4,456,248 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Sep 24, 2021 | Sale | −200,000 | $2.66 | $532.00K | 4,656,248 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Sep 23, 2021 | Sale | −100,000 | $2.77 | $277.00K | 4,856,248 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Sep 22, 2021 | Sale | −100,000 | $2.80 | $280.00K | 4,956,248 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Sep 21, 2021 | Sale | −100,000 | $2.83 | $283.00K | 5,056,248 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Sep 20, 2021 | Sale | −100,000 | $2.90 | $290.00K | 5,156,248 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.